Egrifta (Tesamorelin) Legal, Patent, and FDA Challenges: What Every Woman Should Know Before Considering This Drug

What Is Tesamorelin and Why Does Its Regulatory History Matter to You?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release growth hormone, which in turn raises IGF-1 levels and reduces visceral adipose tissue. The FDA-approved brand, Egrifta, exists specifically to treat the excess belly fat that can accumulate in people living with HIV who are on antiretroviral therapy, a condition called HIV-associated lipodystrophy.

If you are a woman who uses antiretroviral therapy, has significant visceral adiposity, or is exploring newer peptide therapies for metabolic health, understanding how Egrifta reached approval, what its label actually requires, and what legal skirmishes have shaped its market availability directly affects your access, cost, and safety information.

The regulatory story also matters because it exposes a real gap: women, particularly women at different hormonal life stages, were not well-represented in the trials that earned this drug its approval.

FDA Approval Timeline: Two Phases, One Drug

Egrifta's path through the FDA was not a single linear event. There are two distinct approval milestones separated by nearly a decade.

The 2010 Original NDA Approval

The FDA approved tesamorelin on November 10, 2010, under New Drug Application (NDA) 022505. The approval was based primarily on two Phase 3 randomized controlled trials, including the landmark study by Falutz et al. Published in the New England Journal of Medicine in 2007, which demonstrated that tesamorelin 2 mg subcutaneously once daily reduced trunk fat by a mean of approximately 15% versus placebo over 26 weeks in HIV-positive adults on stable antiretroviral regimens.

The approval carried several conditions:

• A Risk Evaluation and Mitigation Strategy (REMS) was initially considered but ultimately the FDA required strong post-market study commitments instead.
• The label explicitly restricted use to HIV-related lipodystrophy only. Off-label use for general obesity or cosmetic body-composition change in the general population was not sanctioned.
• Theratechnologies was required to conduct pediatric studies under the Pediatric Research Equity Act, though tesamorelin has no approved pediatric indication to date.

The 2019 Label Expansion

In 2019, the FDA approved a supplemental NDA that expanded the Egrifta label to include a new, more stable formulation, Egrifta SV (2 mg/vial in a ready-to-use solution). This reformulation addressed prior reconstitution errors and improved dose consistency. The approval did not expand the indication itself but did update the prescribing information with revised storage, preparation, and administration instructions.

The 2019 update also refined the contraindication language around pregnancy and active malignancy, making the risk language more explicit for clinicians prescribing to women of reproductive age.

What the Egrifta Label Actually Says

Reading a drug label is not optional if you are considering this medication. The current Egrifta prescribing information contains several points that specifically affect women.

Approved Dose

The approved dose is 2 mg subcutaneously once daily, injected into the abdomen with the site rotated daily. No dose adjustment is specified for sex, menstrual cycle phase, or menopausal status, which reflects the paucity of pharmacokinetic data in women across hormonal life stages.

Contraindications

The label lists four absolute contraindications:

1. Hypersensitivity to tesamorelin or mannitol
2. Active malignancy (any ongoing or newly diagnosed cancer)
3. Pregnancy
4. Disruption of the hypothalamic-pituitary axis due to prior surgery, trauma, radiation, or hypopituitarism

The malignancy contraindication is especially relevant for women with a personal or family history of breast cancer or gynecologic cancers, since growth hormone axis stimulation is theoretically problematic in hormone-sensitive tumors. The label does not quantify this risk numerically because long-term oncologic data in women with such histories are absent.

Warnings Relevant to Women

The label flags three warnings that women encounter more often than men in clinical practice:

• Fluid retention: Peripheral edema, arthralgias, and carpal tunnel syndrome can occur. Women on oral estrogen, which raises IGF-1 binding protein and can blunt GH response, may have a different fluid-retention profile than men, though the label does not address this directly.
• Glucose intolerance: Tesamorelin raises IGF-1, which can impair insulin sensitivity. Women with PCOS, who already carry a higher baseline risk of insulin resistance, should have fasting glucose and HbA1c checked before starting and every 6 months during therapy.
• IGF-1 elevation: If IGF-1 rises above age- and sex-adjusted normal ranges, the label recommends dose reduction or discontinuation.

Patent Field and Legal Challenges

The patent story around tesamorelin is relevant to you because it directly shapes whether a lower-cost generic or biosimilar version of this peptide could become available.

Core Patent Portfolio

Theratechnologies holds multiple patents covering tesamorelin, falling into two broad categories:

1. Composition-of-matter patents covering the tesamorelin peptide structure and its stabilized acetate salt form.
2. Formulation patents covering the lyophilized powder and later the ready-to-use solution (Egrifta SV), including the mannitol-based excipient system that prevents peptide aggregation.

Because tesamorelin is a 44-amino-acid synthetic peptide rather than a small molecule, it does not fall neatly under the standard Hatch-Waxman abbreviated NDA (ANDA) framework that governs small-molecule generics. Generic applicants would need to file a 505(b)(2) NDA or potentially a biologics license application pathway, both of which carry higher evidentiary bars.

Paragraph IV Challenges and Litigation History

As of the date of this article's last review, no Paragraph IV certification challenging the validity of Theratechnologies' Egrifta patents has resulted in a successful generic entry. Theratechnologies has defended its formulation patents, particularly around the stabilization technology introduced with Egrifta SV, in both U.S. And Canadian jurisdictions.

The Canadian regulatory body, Health Canada, approved tesamorelin separately, and Theratechnologies' domestic patent protections in Canada have similarly been upheld in commercial disputes with compounding pharmacies attempting to produce unapproved tesamorelin versions.

Compounding Pharmacies: A Particular Issue for Women in Telehealth

This is where the regulatory picture becomes directly relevant to women accessing peptide therapies through telehealth platforms, including WomanRx. Because tesamorelin is FDA-approved only for HIV-related lipodystrophy, compounding pharmacies have supplied it off-label for other uses, including visceral fat reduction in peri- and postmenopausal women and in women with PCOS-related metabolic dysfunction.

The FDA has taken the position that tesamorelin, as an approved drug, cannot be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act without meeting specific conditions. In 2023 and 2024, the FDA increased scrutiny of compounded peptides broadly. FDA communications on compounded peptides clarified that copying an approved drug like tesamorelin through a compounding pharmacy is generally not permissible. This enforcement posture has created legal uncertainty for clinicians prescribing compounded tesamorelin off-label.

Women receiving compounded tesamorelin through telehealth channels should understand that the product they receive has not undergone FDA review for sterility, potency, or identity verification in the same manner as Egrifta.

Safety Data: What the Post-Market Evidence Shows

The FDA approval required Theratechnologies to complete post-market safety studies. Here is what the accumulated evidence shows, with particular attention to data in women.

Cardiovascular Safety

The Falutz et al. 2007 NEJM trial enrolled 412 participants and found no significant increase in major adverse cardiovascular events over 26 weeks. A long-term extension study published subsequently showed that the reduction in visceral adipose tissue was maintained at 52 weeks with continued therapy but reversed within 6 months of stopping. Cardiovascular outcomes were not a primary endpoint in these trials, and the studies were not powered to detect rare cardiac events.

Cancer Signal and Women-Specific Concern

No increase in incident malignancy was detected in the pooled clinical trial data. The trials did, however, exclude anyone with a current or recent cancer diagnosis. For women who are breast cancer survivors or who carry BRCA1/BRCA2 mutations, the theoretical concern about growth hormone axis stimulation has not been addressed in a dedicated trial. The current FDA label simply lists active malignancy as a contraindication and does not provide guidance for women in remission.

Fluid Retention and Musculoskeletal Effects

Across the Phase 3 program, peripheral edema occurred in approximately 6% of tesamorelin recipients versus 2% of placebo recipients. Arthralgias and myalgias were also more common with active drug. Women taking oral estrogen, which already promotes some sodium retention, may experience additive fluid effects, though no formal drug-interaction study with estrogen therapy has been published.

Glucose and Insulin: Especially Relevant for Women With PCOS or Perimenopausal Metabolic Shift

Tesamorelin mildly worsens insulin sensitivity. In the key trials, new-onset diabetes or worsening glycemic control occurred in a small but measurable proportion of participants. Women with PCOS, who already have a 50-70% lifetime risk of insulin resistance, and perimenopausal women experiencing estrogen-withdrawal-associated metabolic changes face a compounded glycemic risk that has not been specifically studied. Your clinician should check HbA1c at baseline and every 6 months.

A practical framework for women considering tesamorelin, regardless of indication:

| Life stage | Key pre-treatment check | Main monitoring concern | |---|---|---| | Reproductive years (cycling) | Pregnancy test, glucose, IGF-1 | Cycle disruption, IGF-1 overshoot | | Trying to conceive | Contraindicated. Stop before conception attempt | Fetal safety unknown | | Perimenopause | HbA1c, fasting glucose, lipids | Additive insulin resistance | | Post-menopause | IGF-1 (declines with age), DEXA if osteoporosis risk | Fluid retention if on oral HRT | | HIV-positive (any stage) | CD4 count, current ART regimen, fasting glucose | Drug interactions with PIs |

Pregnancy, Lactation, and Contraception: Required Reading

Tesamorelin is contraindicated in pregnancy. This is not a soft warning. The FDA label assigns it a former Pregnancy Category X equivalent under the current descriptive system, meaning available animal data show fetal harm and the risks outweigh any potential benefit.

Animal Data

In animal reproductive studies, tesamorelin was associated with fetal growth effects at doses relevant to human exposure. No adequate, well-controlled studies in pregnant humans have been conducted, and given the contraindication, none are planned.

What to Do If You Become Pregnant While Taking Egrifta

Stop tesamorelin immediately. Contact your prescriber the same day. The drug has a short half-life (approximately 26 minutes for the parent peptide), so systemic exposure drops quickly after the last dose. Your clinician should document the exposure timing and refer you to a maternal-fetal medicine specialist if the exposure occurred during the first trimester.

Lactation

No data exist on tesamorelin transfer into human breast milk. Given that tesamorelin is a large peptide (molecular weight approximately 5,135 Da), significant oral bioavailability in a nursing infant is unlikely. But "unlikely" is not "absent," and the FDA label recommends against breastfeeding during tesamorelin therapy. The decision to discontinue breastfeeding or discontinue the drug should be made in conversation with your prescriber, weighing the clinical necessity of the medication.

Women living with HIV who are on antiretroviral therapy and who might consider tesamorelin should also note that CDC guidelines and ACOG guidance already address complex infant-feeding decisions in the context of HIV. Tesamorelin adds another layer to that conversation.

Contraception Requirement

Because tesamorelin is contraindicated in pregnancy, women of reproductive potential should use reliable contraception during treatment. The label does not specify a method, but given that tesamorelin can theoretically affect pituitary signaling, your prescriber should confirm that your chosen contraceptive method does not depend solely on cycle tracking. Barrier methods or hormonal contraception with established efficacy are appropriate choices.

Who This Drug Is Right For, and Who It Is Not

Women Who May Benefit (Within Approved Labeling)

• HIV-positive women on stable antiretroviral therapy with clinically significant excess visceral abdominal fat
• Women in this group who have already tried dietary and exercise interventions without sufficient visceral fat reduction
• Women with the above who do not have active cancer, are not pregnant, are not trying to conceive, and have documented normal or near-normal glucose tolerance at baseline

Women for Whom This Drug Is Not Currently Appropriate

• Any woman who is pregnant or planning pregnancy in the near term
• Breastfeeding women
• Women with active malignancy, including breast cancer, ovarian cancer, or cervical cancer currently under treatment
• Women seeking this drug off-label for general cosmetic body composition improvement without an HIV diagnosis, since no FDA-approved indication covers this use and the compounding legal field is uncertain
• Women with poorly controlled type 2 diabetes or significant insulin resistance, since tesamorelin may worsen glycemic control
• Women with hypopituitarism or prior pituitary surgery or radiation

A Note on Off-Label Use in Perimenopause and PCOS

Clinicians and women themselves are increasingly curious about whether tesamorelin might address the visceral fat gain that accompanies the estrogen decline of perimenopause or the metabolic dysfunction of PCOS. The biological rationale is plausible: GH secretion declines with age and with hyperinsulinemia, both of which are common in these populations. The evidence base for off-label use, however, is currently limited to small mechanistic studies, none of which were specifically designed or powered to evaluate tesamorelin in perimenopausal or PCOS populations. ACOG and The Menopause Society have not issued guidance on tesamorelin for these indications.

Women exploring tesamorelin for these purposes should have an explicit conversation with their prescriber about the distinction between FDA-approved use and off-label use, the compounding legal status, and the absence of long-term safety data in hormonally distinct female populations.

The Evidence Gap: Women Have Been Under-Represented

This deserves plain language. The key trials that earned Egrifta its FDA approval enrolled predominantly male participants, reflecting the HIV epidemic demographics of the mid-2000s when the studies were designed. Falutz et al. 2007 enrolled 412 participants; the proportion of women enrolled was small enough that female-specific subgroup analyses were underpowered.

This means that the approved dose of 2 mg daily, the expected IGF-1 response curve, the fluid-retention incidence, and the glycemic impact have all been characterized primarily in men. Women metabolize peptides differently across their menstrual cycle, with estrogen affecting GH pulsatility and IGF-1 sensitivity. A postmenopausal woman on oral estrogen therapy, for example, may require higher GH secretion to achieve equivalent IGF-1 levels because oral estrogen induces first-pass hepatic resistance to GH signaling, a phenomenon documented in women receiving GH replacement for GH deficiency but not specifically studied with tesamorelin.

The FDA's post-market safety commitments for Egrifta did not require sex-disaggregated re-analysis or female-specific pharmacokinetic bridging studies. That gap remains open.

Regulatory Outlook: What May Change

Theratechnologies has faced commercial pressure as the HIV treatment field has changed and the prevalence of severe lipodystrophy has declined with newer, less metabolically new antiretroviral regimens. The company has explored label expansions for other indications, including non-alcoholic fatty liver disease (NAFLD), where tesamorelin showed early promise in a small trial, though no supplemental NDA for NAFLD has been approved as of this writing.

On the generic competition front, the peptide formulation complexity and the active patent protections around Egrifta SV mean that a commercially available generic is unlikely in the near term. Women who need this drug under its approved indication should expect branded pricing to persist, and should work with their prescribers and insurance plans to access manufacturer patient-assistance programs if cost is a barrier.

For women considering compounded tesamorelin for off-label purposes, the FDA's increased enforcement posture toward compounded peptides means that availability through compounding pharmacies may become less consistent. Following the FDA's compounding Q&A page for updates is advisable.